BioRestorative Therapies, Inc. Engages Access BIO To Support Advancement Of Brtxdisc™ Program Into Clinical Studies

JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, announces the engagement of Access BIO, L.C. to provide strategic preclinical and regulatory consulting services related to the Company’s brtxDISC™ program. Initially Access BIO will help the Company prepare for pre-Investigational New Drug (IND) and IND meetings with the U.S. Food and Drug Administration (FDA). This represents the next stage in advancing the Company's brtxDISC™ procedure into the clinic.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC